This study aims to investigate the significance of anti‐FIRΔexon2 Abs, and whether it increases the specificity and accuracy of CRC diagnoses with other clinically available tumor markers, such as anti‐p53 Abs, CEA, and CA19‐9, as reported in other cancer types.26, 27. The gene discussed is TP53; the disease is cancer.